GIVAX
Pre-clinicalGIVAX is developing a new class of vaccines to protect children from severe gastroenteritis caused by rotavirus and norovirus. Leveraging our novel platform technology, we are transforming the future of vaccine development.
Founded
2021
Focus
VaccinesViral Technology
About
GIVAX is developing a new class of vaccines to protect children from severe gastroenteritis caused by rotavirus and norovirus. Leveraging our novel platform technology, we are transforming the future of vaccine development.
Company Info
TypePrivate
Founded2021
LocationCambridge, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile